237 related articles for article (PubMed ID: 37675109)
1.
Mac Donald A; Guipouy D; Lemieux W; Harvey M; Bordeleau LJ; Guay D; Roméro H; Li Y; Dion R; Béland K; Haddad E
Front Immunol; 2023; 14():1231916. PubMed ID: 37675109
[TBL] [Abstract][Full Text] [Related]
2. CRISPR-Cas9 based gene editing of the immune checkpoint NKG2A enhances NK cell mediated cytotoxicity against multiple myeloma.
Bexte T; Alzubi J; Reindl LM; Wendel P; Schubert R; Salzmann-Manrique E; von Metzler I; Cathomen T; Ullrich E
Oncoimmunology; 2022; 11(1):2081415. PubMed ID: 35694192
[TBL] [Abstract][Full Text] [Related]
3. Blocking expression of inhibitory receptor NKG2A overcomes tumor resistance to NK cells.
Kamiya T; Seow SV; Wong D; Robinson M; Campana D
J Clin Invest; 2019 May; 129(5):2094-2106. PubMed ID: 30860984
[TBL] [Abstract][Full Text] [Related]
4. Virus-free CRISPR knock-in of a chimeric antigen receptor into
Shankar K; Zingler-Hoslet I; Shi L; Katta V; Russell BE; Tsai SQ; Capitini CM; Saha K
bioRxiv; 2024 Feb; ():. PubMed ID: 38405747
[TBL] [Abstract][Full Text] [Related]
5.
Guo X; Mahlakõiv T; Ye Q; Somanchi S; He S; Rana H; DiFiglia A; Gleason J; van der Touw W; Hariri R; Zhang X
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33741730
[TBL] [Abstract][Full Text] [Related]
6. HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C.
Braud VM; Allan DS; O'Callaghan CA; Söderström K; D'Andrea A; Ogg GS; Lazetic S; Young NT; Bell JI; Phillips JH; Lanier LL; McMichael AJ
Nature; 1998 Feb; 391(6669):795-9. PubMed ID: 9486650
[TBL] [Abstract][Full Text] [Related]
7. Enhancing Natural Killer and CD8
Ravindranath MH; Filippone EJ; Devarajan A; Asgharzadeh S
Monoclon Antib Immunodiagn Immunother; 2019 Apr; 38(2):38-59. PubMed ID: 31009335
[TBL] [Abstract][Full Text] [Related]
8. The natural killer cell-mediated killing of autologous dendritic cells is confined to a cell subset expressing CD94/NKG2A, but lacking inhibitory killer Ig-like receptors.
Della Chiesa M; Vitale M; Carlomagno S; Ferlazzo G; Moretta L; Moretta A
Eur J Immunol; 2003 Jun; 33(6):1657-66. PubMed ID: 12778484
[TBL] [Abstract][Full Text] [Related]
9. NKG2A Expression Is Not
Mahaweni NM; Ehlers FAI; Sarkar S; Janssen JWH; Tilanus MGJ; Bos GMJ; Wieten L
Front Immunol; 2018; 9():1415. PubMed ID: 29988376
[TBL] [Abstract][Full Text] [Related]
10. The inhibitory NK cell receptor CD94/NKG2A and the activating receptor CD94/NKG2C bind the top of HLA-E through mostly shared but partly distinct sets of HLA-E residues.
Wada H; Matsumoto N; Maenaka K; Suzuki K; Yamamoto K
Eur J Immunol; 2004 Jan; 34(1):81-90. PubMed ID: 14971033
[TBL] [Abstract][Full Text] [Related]
11. Inhibitory NKG2A and activating NKG2D and NKG2C natural killer cell receptor genes: susceptibility for rheumatoid arthritis.
Park KS; Park JH; Song YW
Tissue Antigens; 2008 Oct; 72(4):342-6. PubMed ID: 18700876
[TBL] [Abstract][Full Text] [Related]
12. Human NK cells: surface receptors, inhibitory checkpoints, and translational applications.
Sivori S; Vacca P; Del Zotto G; Munari E; Mingari MC; Moretta L
Cell Mol Immunol; 2019 May; 16(5):430-441. PubMed ID: 30778167
[TBL] [Abstract][Full Text] [Related]
13. NKG2C+ NK Cells for Immunotherapy of Glioblastoma Multiforme.
Murad S; Michen S; Becker A; Füssel M; Schackert G; Tonn T; Momburg F; Temme A
Int J Mol Sci; 2022 May; 23(10):. PubMed ID: 35628668
[TBL] [Abstract][Full Text] [Related]
14. Cytomegalovirus: an unlikely ally in the fight against blood cancers?
Bigley AB; Baker FL; Simpson RJ
Clin Exp Immunol; 2018 Sep; 193(3):265-274. PubMed ID: 29737525
[TBL] [Abstract][Full Text] [Related]
15. Targeting human leukocyte antigen G with chimeric antigen receptors of natural killer cells convert immunosuppression to ablate solid tumors.
Jan CI; Huang SW; Canoll P; Bruce JN; Lin YC; Pan CM; Lu HM; Chiu SC; Cho DY
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34663641
[TBL] [Abstract][Full Text] [Related]
16. CD155 blockade enhances allogeneic natural killer cell-mediated antitumor response against osteosarcoma.
Cho MM; Song L; Quamine AE; Szewc F; Shi L; Ebben JD; Turicek DP; Kline JM; Burpee DM; Lafeber EO; Phillips MF; Ceas AS; Erbe AK; Capitini CM
bioRxiv; 2024 Jun; ():. PubMed ID: 37333207
[TBL] [Abstract][Full Text] [Related]
17. HLA-E protects glioma cells from NKG2D-mediated immune responses in vitro: implications for immune escape in vivo.
Wischhusen J; Friese MA; Mittelbronn M; Meyermann R; Weller M
J Neuropathol Exp Neurol; 2005 Jun; 64(6):523-8. PubMed ID: 15977644
[TBL] [Abstract][Full Text] [Related]
18. Inhibitory NKG2A
Vietzen H; Staber PB; Berger SM; Furlano PL; Kühner LM; Lubowitzki S; Pichler A; Strassl R; Cornelissen JJ; Puchhammer-Stöckl E
Front Immunol; 2023; 14():1183788. PubMed ID: 37426645
[TBL] [Abstract][Full Text] [Related]
19. Expression of p58.2 or CD94/NKG2A inhibitory receptors in an NK-like cell line, YTINDY, leads to HLA Class I-mediated inhibition of cytotoxicity in the p58.2- but not the CD94/NKG2A-expressing transfectant.
Lin Chua H; Brahmi Z
Cell Immunol; 2002 Sep; 219(1):57-70. PubMed ID: 12473268
[TBL] [Abstract][Full Text] [Related]
20. NK cells and ILCs in tumor immunotherapy.
Sivori S; Pende D; Quatrini L; Pietra G; Della Chiesa M; Vacca P; Tumino N; Moretta F; Mingari MC; Locatelli F; Moretta L
Mol Aspects Med; 2021 Aug; 80():100870. PubMed ID: 32800530
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]